Search Results - "Schiff, Rachel"

HER2: biology, detection, and clinical implications by Gutierrez, Carolina, Schiff, Rachel

“…HER2 is a membrane tyrosine kinase and oncogene that is overexpressed and gene amplified in about 20% of breast cancers. When activated it provides the cell…”
Get full text

Mechanisms of endocrine resistance in breast cancer by Osborne, C Kent, Schiff, Rachel

“…The estrogen receptor (ER) pathway plays a pivotal role in breast cancer development and progression. Endocrine therapy to block the ER pathway is highly…”
Get full text

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer by Jeselsohn, Rinath, Buchwalter, Gilles, De Angelis, Carmine, Brown, Myles, Schiff, Rachel

“…Key Points Over the past 18 months, recurrent activating mutations within the oestrogen receptor α (ER) LBD have been detected in 15–20% of patients with…”
Get full text

Development and Relationships Between Phonological Awareness, Morphological Awareness and Word Reading in Spoken and Standard Arabic by Schiff, Rachel, Saiegh-Haddad, Elinor

“…This study addressed the development of and the relationship between foundational metalinguistic skills and word reading skills in Arabic. It compared…”
Get full text

Targeting HER2 for the Treatment of Breast Cancer by Rimawi, Mothaffar F, Schiff, Rachel, Osborne, C. Kent

“…HER2 (ErbB2), a member of the HER family of tyrosine kinase receptors (HER1-4), is a major driver of tumor growth in 20% of breast cancers. Treatment with the…”
Get full text

Towards personalized treatment for early stage HER2-positive breast cancer by Goutsouliak, Kristina, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, De Angelis, Carmine, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel

“…Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized…”
Get full text

The FBXW2–MSX2–SOX2 axis regulates stem cell property and drug resistance of cancer cells by Yin, Yuan, Xie, Chuan-Ming, Li, Hua, Tan, Mingjia, Chen, Guoan, Schiff, Rachel, Xiong, Xiufang, Sun, Yi

“…SOX2 is a key transcription factor that plays critical roles in maintaining stem cell property and conferring drug resistance. However, the underlying…”
Get full text

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance by Arpino, Grazia, Wiechmann, Lisa, Osborne, C. Kent, Schiff, Rachel

“…Breast cancer evolution and tumor progression are governed by the complex interactions between steroid receptor [estrogen receptor (ER) and progesterone…”
Get full text

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer by Jeselsohn, Rinath, De Angelis, Carmine, Brown, Myles, Schiff, Rachel

“…Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number of patients with metastatic ER+ breast cancer and evolve…”
Get full text

Au Nanomatryoshkas as Efficient Near-Infrared Photothermal Transducers for Cancer Treatment: Benchmarking against Nanoshells by Ayala-Orozco, Ciceron, Urban, Cordula, Knight, Mark W, Urban, Alexander Skyrme, Neumann, Oara, Bishnoi, Sandra W, Mukherjee, Shaunak, Goodman, Amanda M, Charron, Heather, Mitchell, Tamika, Shea, Martin, Roy, Ronita, Nanda, Sarmistha, Schiff, Rachel, Halas, Naomi J, Joshi, Amit

“…Au nanoparticles with plasmon resonances in the near-infrared (NIR) region of the spectrum efficiently convert light into heat, a property useful for the…”
Get full text

An epigenomic approach to therapy for tamoxifen-resistant breast cancer by Feng, Qin, Zhang, Zheng, Shea, Martin J, Creighton, Chad J, Coarfa, Cristian, Hilsenbeck, Susan G, Lanz, Rainer, He, Bin, Wang, Lei, Fu, Xiaoyong, Nardone, Agostina, Song, Yongcheng, Bradner, James, Mitsiades, Nicholas, Mitsiades, Constantine S, Osborne, C Kent, Schiff, Rachel, O'Malley, Bert W

“…Tamoxifen has been a frontline treatment for estrogen receptor alpha （ERα）-positive breast tumors in premenopausal women. However, resistance to tamoxifen…”
Get full text

Metastasis dormancy in estrogen receptor-positive breast cancer by Zhang, Xiang H-F, Giuliano, Mario, Trivedi, Meghana V, Schiff, Rachel, Osborne, C Kent

“…About 20% to 40% of patients with breast cancer eventually develop recurrences in distant organs, which are often not detected until years to decades after the…”
Get full text

Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities by MASSARWEH, Suleiman, SCHIFF, Rachel

“…Two thirds of breast cancers express the estrogen receptor (ER), which contributes to tumor development and progression. ER-targeted therapy is therefore…”
Get full text

Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk by Massarweh, Suleiman, Schiff, Rachel

“…Targeting the estrogen receptor (ER) is the oldest form of molecular targeted therapy, and the widespread use of the selective estrogen receptor modulator…”
Get full text

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer by Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

“…Forkhead box A1 (FOXA1) is a pioneer factor that facilitates chromatin binding and function of lineage-specific and oncogenic transcription factors…”
Get full text

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis by Schettini, Francesco, Pascual, Tomás, Conte, Benedetta, Chic, Nuria, Brasó-Maristany, Fara, Galván, Patricia, Martínez, Olga, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Fernández-Martinez, Aranzazu, Rognoni, Carla, Griguolo, Gaia, Guarneri, Valentina, Conte, Pier Franco, Locci, Mariavittoria, Brase, Jan C., Gonzalez-Farre, Blanca, Villagrasa, Patricia, De Placido, Sabino, Schiff, Rachel, Veeraraghavan, Jamunarani, Rimawi, Mothaffar F., Osborne, C. Kent, Pernas, Sonia, Perou, Charles M., Carey, Lisa A., Prat, Aleix

“…•We correlated the breast cancer intrinsic subtypes with pCR in HER2+ disease.•The HER2-E subtype was significantly and consistently associated with pCR after…”
Get full text

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 by RIMAWI, Mothaffar F, MAYER, Ingrid A, SCHIFF, Rachel, KENT OSBORNE, C, CHANG, Jenny C, FORERO, Andres, NANDA, Rita, GOETZ, Matthew P, RODRIGUEZ, Angel A, PAVLICK, Anne C, TAO WANG, HILSENBECK, Susan G, GUTIERREZ, Carolina

“…We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified human xenografts in mice by inhibition of the HER2 pathway…”
Get full text

The changing role of ER in endocrine resistance by Nardone, Agostina, De Angelis, Carmine, Trivedi, Meghana V, Osborne, C. Kent, Schiff, Rachel

“…Abstract Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast tumors. Although endocrine therapy targeting ER is highly…”
Get full text

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models by XIAOMEI ZHANG, CLAERHOUT, Sofie, HELEN WONG, FUQUA, Suzanne W, CONTRERAS, Alejandro, GUTIERREZ, Carolina, JIAN HUANG, SUFENG MAO, PAVLICK, Anne C, FROEHLICH, Amber M, WU, Meng-Fen, TSIMELZON, Anna, PRATT, Aleix, HILSENBECK, Susan G, CHEN, Edward S, ZULOAGA, Pavel, SHAW, Chad A, RIMAWI, Mothaffar F, PEROU, Charles M, MILLS, Gordon B, CHANG, Jenny C, LEWIS, Michael T, DOBROLECKI, Lacey E, PETROVIC, Ivana, QING LAI, LANDIS, Melissa D, WIECHMANN, Lisa, SCHIFF, Rachel, GIULIANO, Mario

“…Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that…”
Get full text

pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo by Meerbrey, Kristen L, Hu, Guang, Kessler, Jessica D, Roarty, Kevin, Li, Mamie Z, Fang, Justin E, Herschkowitz, Jason I, Burrows, Anna E, Ciccia, Alberto, Sun, Tingting, Schmitt, Earlene M, Bernardi, Ronald J, Fu, Xiaoyong, Bland, Christopher S, Cooper, Thomas A, Schiff, Rachel, Rosen, Jeffrey M, Westbrook, Thomas F, Elledge, Stephen J

“…The discovery of RNAi has revolutionized loss-of-function genetic studies in mammalian systems. However, significant challenges still remain to fully exploit…”
Get full text